Growth of Astrocytomas in the Human Tumor Clonogenic Assay and Sensitivity to Mismatched dsRNA and Interferons
| Autor: | David R. Strayer, William A. Carter, Albert W. Cook, Florence Nidzgorski, Jan Weisband, Perry Black |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
Poly U
Cancer Research Astrocytoma Cell Line law.invention Colony-Forming Units Assay law Interferon Humans Medicine Clonogenic assay Beta (finance) Tumor Stem Cell Assay Dose-Response Relationship Drug Brain Neoplasms business.industry Interferon-beta medicine.disease Carmustine Recombinant Proteins Human tumor RNA silencing Poly I-C Oncology Cell culture Interferon Type I Immunology Cancer research Recombinant DNA Glioblastoma business Interferon beta-1a Interferon beta-1b Polyribonucleotides medicine.drug |
| Zdroj: | American Journal of Clinical Oncology. 10:281-284 |
| ISSN: | 0277-3732 |
| DOI: | 10.1097/00000421-198708000-00003 |
| Popis: | Nine astrocytoma specimens were received from seven patients and processed for testing in the human tumor clonogenic assay (HTCA). Cells derived from these specimens were challenged with human natural alpha-interferon (alpha-IFN) and beta interferon (beta-IFN), recombinant beta interferon (beta ser-IFN), and mismatched double-stranded (ds) RNA (Ampligen). Six of the astrocytoma specimens formed adequate colonies for drug sensitivity testing (greater than or equal to 30 colonies/plate), and all were high-grade (III-IV) tumors. Sensitivity was defined as a greater than or equal to 50% decrease in tumor colony formation following drug exposure and was observed with alpha-IFN (2/4), beta-IFN (3/4), and mismatched dsRNA (4/5) exposure. No decrease in colony growth was observed after recombinant beta ser-IFN exposure, and in 2 of 3 cases, colony formation was stimulated. The sensitivity of 75 non-CNS solid tumors to mismatched dsRNA was compared to the high-grade astrocytomas in the HTCA. Of the 10 additional histologic tumor types studied, carcinoid and renal cell carcinomas exhibited the greatest sensitivity to mismatched dsRNA: 63% and 52%, respectively. However, in comparison, 80% of the high-grade astrocytomas were sensitive, demonstrating that these gliomas are among the most sensitive of human tumors to mismatched dsRNA in vitro. Clinical trials of interferons and mismatched dsRNA, coupled with in vitro sensitivity studies, should further define their therapeutic potential. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|